CD274 and neoplasm: Recent translational research studies in the setting of TNBC have shown that several patient groups received less benefit from anti–PD-(L)1 therapy, namely patients with “cold” tumors (i.e., tumors not infiltrated by immune cells and showing no signs of an immune response), those with an immune-excluded phenotype (i.e., the immune reaction remains outside of the tumor core), or patients with tumors with an immune-suppressed signature (3, 4).